Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DARATUMUMAB Cause Intentional product use issue? 711 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 711 reports of Intentional product use issue have been filed in association with DARATUMUMAB (DARZALEX). This represents 2.6% of all adverse event reports for DARATUMUMAB.

711
Reports of Intentional product use issue with DARATUMUMAB
2.6%
of all DARATUMUMAB reports
56
Deaths
108
Hospitalizations

How Dangerous Is Intentional product use issue From DARATUMUMAB?

Of the 711 reports, 56 (7.9%) resulted in death, 108 (15.2%) required hospitalization, and 12 (1.7%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 711 reports have been filed with the FAERS database.

What Other Side Effects Does DARATUMUMAB Cause?

Plasma cell myeloma (2,980) Infusion related reaction (2,557) Off label use (2,494) Pneumonia (1,450) Neutropenia (1,351) Drug ineffective (1,110) Thrombocytopenia (1,089) Death (1,088) Pyrexia (1,032) Dyspnoea (996)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which DARATUMUMAB Alternatives Have Lower Intentional product use issue Risk?

DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ DARATUMUMAB vs DARBEPOETIN ALFA DARATUMUMAB vs DARIDOREXANT DARATUMUMAB vs DARIFENACIN HYDROBROMIDE DARATUMUMAB vs DAROLUTAMIDE

Related Pages

DARATUMUMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue DARATUMUMAB Demographics